CA3016867A1 - Polypeptide gb de cytomegalovirus humain - Google Patents

Polypeptide gb de cytomegalovirus humain Download PDF

Info

Publication number
CA3016867A1
CA3016867A1 CA3016867A CA3016867A CA3016867A1 CA 3016867 A1 CA3016867 A1 CA 3016867A1 CA 3016867 A CA3016867 A CA 3016867A CA 3016867 A CA3016867 A CA 3016867A CA 3016867 A1 CA3016867 A1 CA 3016867A1
Authority
CA
Canada
Prior art keywords
polypeptide
seq
amino acid
acid sequence
cmv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA3016867A
Other languages
English (en)
Inventor
Xiaoyuan Sherry CHI
Xinzhen Yang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Publication of CA3016867A1 publication Critical patent/CA3016867A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16171—Demonstrated in vivo effect

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne un polypeptide qui comprend au moins une mutation au niveau de la région de boucle de fusion 1 et/ou au niveau de la région de boucle de fusion 2 et/ou au niveau du site de clivage de type furine d'un polypeptide gB de cytomégalovirus humain. Dans un mode de réalisation, le polypeptide subit un changement de conformation structurale en réponse à un changement de pH.
CA3016867A 2016-03-11 2017-03-09 Polypeptide gb de cytomegalovirus humain Abandoned CA3016867A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662307423P 2016-03-11 2016-03-11
US62/307,423 2016-03-11
PCT/IB2017/051401 WO2017153954A1 (fr) 2016-03-11 2017-03-09 Polypeptide gb de cytomégalovirus humain

Publications (1)

Publication Number Publication Date
CA3016867A1 true CA3016867A1 (fr) 2017-09-14

Family

ID=58413151

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3016867A Abandoned CA3016867A1 (fr) 2016-03-11 2017-03-09 Polypeptide gb de cytomegalovirus humain

Country Status (3)

Country Link
EP (1) EP3426676A1 (fr)
CA (1) CA3016867A1 (fr)
WO (1) WO2017153954A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020121983A1 (fr) 2018-12-10 2020-06-18 Ｋｍバイオロジクス株式会社 Vaccin pour la prévention ou le traitement d'une infection congénitale par le cytomégalovirus
JP7271794B2 (ja) * 2020-06-09 2023-05-11 Ｋｍバイオロジクス株式会社 サイトメガロウイルスのｇＢとペンタマーとの融合タンパク質及び該融合タンパク質を含むワクチン

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0832638B2 (ja) 1989-05-25 1996-03-29 カイロン コーポレイション サブミクロン油滴乳剤を含んで成るアジュバント製剤
CN106924729B (zh) 2008-07-16 2021-03-02 生物医学研究学会 人巨细胞病毒中和抗体及其应用
AU2011315447A1 (en) * 2010-10-15 2013-05-09 Glaxosmithkline Biologicals S.A. Cytomegalovirus gB antigen
EP3031822A1 (fr) * 2014-12-08 2016-06-15 Novartis AG Antigènes du cytomégalovirus

Also Published As

Publication number Publication date
EP3426676A1 (fr) 2019-01-16
WO2017153954A1 (fr) 2017-09-14

Similar Documents

Publication Publication Date Title
US20230109393A1 (en) Designer peptides and proteins for the detection, prevention and treatment of coronavirus disease, 2019 (covid-19)
US10364273B2 (en) Cytomegalovirus antigens
US20150086578A1 (en) Human cytomegalovirus vaccine
US11629172B2 (en) Human cytomegalovirus gB polypeptide
CN107531761A (zh) 巨细胞病毒抗原及其用途
TWI445547B (zh) 登革熱病毒胜肽疫苗及其製備與使用方法
US11857622B2 (en) Human cytomegalovirus GB polypeptide
KR100927221B1 (ko) Ｅ형 간염 바이러스의 폴리펩티드 단편, 그를 이용한 백신조성물 및 진단용 키트
KR20130041185A (ko) 디자이너(designer) 펩티드-기반 pcv2 백신
US20180015159A1 (en) Cmv antigens and uses thereof
JP4750024B2 (ja) Ｓａｒｓの免疫原を発現するベクター、そのようなベクター又はその発現産物を含有する組成物、並びにその作製及び使用の方法及びアッセイ
CN111132692A (zh) 包含寨卡病毒抗原的病毒样颗粒
KR20220009959A (ko) Csfv 서브유닛 백신
US10611800B2 (en) Human cytomegalovirus gB polypeptide
CA3016867A1 (fr) Polypeptide gb de cytomegalovirus humain
KR20190096965A (ko) 선천적 진전 a를 야기하는 신규한 페스티바이러스의 단리
KR101966841B1 (ko) 지카바이러스 e 단백질 유래의 재조합 항원 및 이의 용도
KR20230054719A (ko) Sars-cov-2 감염에 대한 백신
Shigeki et al. Characterization of pseudorabies virus neutralization antigen glycoprotein gIII produced in insect cells by a baculovirus expression vector
WO1995004147A1 (fr) Produits de synthese recombinants utilisant des sequences de remplacement dans les regions hypervariables
CN117720628A (zh) 一种呼吸道合胞病毒二价抗原制备方法和应用
CN116472280A (zh) 针对SARS-CoV-2感染的疫苗

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20220325

FZDE Discontinued

Effective date: 20220325